Table 6.

Factors influencing the seroprevalence of anti-CSP antibodies

	Number (%)	OR (95% CI)	ORa (95% CI)	p value
Age group (year)
<1	62 (42.47%)	1	1
1–4	378 (37.8%)	0.82 (0.57–1.17)	0.85 (0.59–1.21)	0.38
5–10	313 (43.53%)	1.04 (0.73–1.5)	1.08 (0.75–1.56)	0.66
Gender
Female	376 (41%)	1	1
Male	377 (39.77%)	0.95 (0.78–1.14)	0.98 (0.81–1.19)	0.86
Nutritional status
Stunting	289 (43.72%)	1.24 (1.02–1.5)	1.09 (0.85–1.4)	0.45
Underweight	191 (38.43%)	0.89 (0.72–1.1)	0.88 (0.64–1.09)	0.19
Wasting	55 (28.06%)	0.54 (0.4 0.75)	0.61 (0.43–0.86)	0.005
Anemia
No	207 (40.19%)	1	1
Yes	546 (40.44%)	1.01 (0.82–1.24)	0.87 (0.69–1.1)	0.25
Malaria parasite
No	710 (40.07%)	1	1
Yes	43 (46.24%)	1.28 (0.085–1.95)	1.2 (0.78–1.84)	0.4
Residence area
Keur Soce	297 (29.73%)	1	1
Velingara	456 (52.66%)	2.63 (2.17–3.17)	2.63 (2.13–3.24)	<10−3